2 Growth Stocks to Buy For 2026 and Beyond

Vertex, up ~13% YTD, is banking on new launches (Journavx) and commercial momentum for Casgevy plus late-stage pipeline assets (zimislecel for T1D, inaxaplin for APOL1 kidney disease) to sustain revenue and drive near‑term catalysts into 2026 after earlier pipeline setbacks. DexCom reported Q3 revenue up 22% YoY to $1.2 billion, with its OTC Stelo product generating over $100 million in revenue after 12 months; management argues CGMs remain complementary to GLP‑1 therapies despite limited device recalls and investor concerns that diabetes drugs could reduce CGM demand.

Analysis

Market structure: Winners are Vertex (VRTX) with durable CF cash flows and optionality from Journavx, Casgevy and late‑stage assets (zimislecel, inaxaplin), and DexCom (DXCM) if OTC Stelo scales beyond $100M/year. Losers include smaller CGM suppliers and niche device OEMs who lose share on recalls or fail to execute OTC transitions; payors are the marginal price setters as new launches meet coverage decisions. Supply/demand: CGM demand can broaden from insulin users to ~33%+ prediabetic population — an addressable market expansion that could multiply unit demand 2x–3x over 3–5 years if uptake continues and recalls remain contained. Cross-asset: positive biotech catalysts in 2026 would tighten risk premia (compress CDS spreads, lift equity implied vols if binary events near) and modestly increase risk‑on flows (pressure Treasuries), while device recall headlines drive short-term vols and call skew in DXCM/VRTX options.

Risk assessment: Tail risks include a major safety/regulatory setback (FDA recall expansion or pivotal failure for zimislecel) that can send VRTX/DXCM -20% to -40% within days. Time horizons: immediate (days) — recall headlines, 3–6 months — payer coverage and Stelo traction, 12–36 months — launch readouts and commercial scale; quantify: miss on payer coverage could shave 10–30% of projected launch revenue. Hidden dependencies: reimbursement decisions, manufacturing scale, and physician adoption curves; catalysts to watch: zimislecel pivotal readout, Journavx real‑world uptake, Stelo monthly revenue growth and FDA remediation updates.

Trade implications: Direct: establish a measured long in VRTX (2–3% portfolio) phased over 3 months to capture 2026 commercial catalysts; use Jan‑2027 LEAPS call spreads to lever upside while capping cost. For DXCM, maintain a smaller tactical long (1–2%), add on >10% pullback, and use short‑dated put protection if recalls worsen; consider a calendar put spread to monetize elevated near‑term vol. Sector: overweight biotech +2% vs benchmark, trim small‑cap med‑device exposure by 1–2%. Entry/exit: scale into VRTX at current levels, take profits at +30%/+50% or cut at -20%; exit DXCM if FDA issues extend beyond 90 days or Stelo growth stalls sequentially over two quarters.

Contrarian angles: Consensus underestimates Vertex’s multi‑product commercialization momentum — market may be underpricing a 20–40% EPS upside in 12–24 months if zimislecel and inaxaplin succeed and Journavx payer wins accelerate. Conversely, fear around CGM obsolescence from GLP‑1 or cell therapies is likely overdone short‑term; historically device recalls produce sharp but transient share declines (Medtronic examples) with recovery in 6–12 months if remediation is effective. Unintended consequence: strong VRTX success in T1D could structurally reduce insulin‑dependent CGM TAM — hedge DXCM exposure as a cross‑asset asymmetric risk.

Key Decisions for Investors

• Establish a phased long position in VRTX equal to 2–3% of portfolio over the next 90 days (build in 3 tranches); complement with Jan‑2027 LEAPS call spreads (buy‑calls and sell higher strike calls) to target 30–50% upside while limiting premium risk; trim to half size if shares rise +30% or cut to zero if negative pivotal readout for zimislecel occurs.
• Initiate a tactical 1–2% long in DXCM, add an equal increment only on a >10% pullback; buy 3–6 month protection (puts) sized to limit downside to -15% if FDA recall extends past 90 days; sell short‑dated covered calls on incremental position if DXCM rallies >25% to monetize premium.
• Implement a pair/sector tilt: overweight biotech by +2% vs benchmark and reduce small‑cap med‑device exposure by -1–2% immediately; reallocate proceeds into VRTX and select late‑stage biotechs with clear 12–36 month catalysts.
• Hedge portfolio tail risk: purchase index‑level biotech put protection (e.g., 3–6 month put spread on IBB or XBI) sized to offset a 5% portfolio drawdown if multiple regulatory failures occur in H1 2026.
• Monitor three triggers closely and act within specified windows: (1) Vertex zimislecel pivotal readout date — if delayed beyond expected 12–18 months, reduce VRTX exposure by 50%; (2) Journavx payer wins — require at least two national payer formulary wins within 6 months or reassess revenue forecasts down 20%; (3) DexCom recall remediation — if FDA reports unresolved safety gaps after 90 days, cut DXCM position by 75%.